614 related articles for article (PubMed ID: 11437399)
21. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
Rebbeck TR; Wang Y; Kantoff PW; Krithivas K; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Brunet JS; Vesprini D; Garber JE; Lynch HT; Weber BL; Brown M
Cancer Res; 2001 Jul; 61(14):5420-4. PubMed ID: 11454686
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility.
Wu MH; Chou YC; Yu CP; Yang T; You SL; Chen CJ; Sun CA
Eur J Cancer Prev; 2008 Aug; 17(4):317-22. PubMed ID: 18562955
[TBL] [Abstract][Full Text] [Related]
23. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population.
Silva Neto B; Koff WJ; Biolchi V; Brenner C; Biolo KD; Spritzer PM; Brum IS
Cancer Invest; 2008 Feb; 26(1):74-80. PubMed ID: 18181049
[TBL] [Abstract][Full Text] [Related]
24. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines.
Liede A; Zhang W; De Leon Matsuda ML; Tan A; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):848-52. PubMed ID: 14504193
[TBL] [Abstract][Full Text] [Related]
26. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
[TBL] [Abstract][Full Text] [Related]
27. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
28. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Mol Carcinog; 2010 Jun; 49(6):545-55. PubMed ID: 20306497
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
30. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA; Krumroy LM; Rostai M; Casey G
Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
[TBL] [Abstract][Full Text] [Related]
31. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.
Haraldsson K; Loman N; Zhang QX; Johannsson O; Olsson H; Borg A
Cancer Res; 1998 Apr; 58(7):1367-71. PubMed ID: 9537231
[TBL] [Abstract][Full Text] [Related]
32. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
33. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
[TBL] [Abstract][Full Text] [Related]
34. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
35. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor polymorphisms and the incidence of prostate cancer.
Chen C; Lamharzi N; Weiss NS; Etzioni R; Dightman DA; Barnett M; DiTommaso D; Goodman G
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1033-40. PubMed ID: 12376504
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Phelan CM; Rebbeck TR; Weber BL; Devilee P; Ruttledge MH; Lynch HT; Lenoir GM; Stratton MR; Easton DF; Ponder BA; Cannon-Albright L; Larsson C; Goldgar DE; Narod SA
Nat Genet; 1996 Mar; 12(3):309-11. PubMed ID: 8589723
[TBL] [Abstract][Full Text] [Related]
38. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study.
Chatterjee N; Shih J; Hartge P; Brody L; Tucker M; Wacholder S
Genet Epidemiol; 2001 Sep; 21(2):123-38. PubMed ID: 11507721
[TBL] [Abstract][Full Text] [Related]
39. Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
Pääkkönen K; Sauramo S; Sarantaus L; Vahteristo P; Hartikainen A; Vehmanen P; Ignatius J; Ollikainen V; Kääriäinen H; Vauramo E; Nevanlinna H; Krahe R; Holli K; Kere J
Genet Epidemiol; 2001 Feb; 20(2):239-46. PubMed ID: 11180449
[TBL] [Abstract][Full Text] [Related]
40. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
